title: The effects of different hormone treatment on endothelial function in healthy postmenopausal women.
abstract: We aimed to compare the effects of different types of hormone treatment (HT) on endothelial function by means of brachial artery ultrasonographic examination in postmenopausal women. Sixty-two healthy postmenopausal women were included in this study. Subjects were assigned to one of the five groups receiving 6 months of treatment [estrogen (conjugated estrogen), estrogen (conjugated estrogen) plus progesterone (medroxyprogesterone acetate; MPA), raloxifene, tibolone or control]. Endothelial function was assessed by measurement of flow-mediated dilatation (FMD) and nitrate-dependent dilatation in the brachial artery. At the end of 6 months, FMD values were found to be significantly increased in women with HT use than the control group (p = 0.001). In subgroups, FMD increased significantly in the estrogen [12 ± 7 versus 25 ± 8, p = 0.001] and raloxifene groups [7 ± 5 versus 11 ± 3, p < 0.01] compared to tibolone and estrogen plus progesterone groups. In conclusion, endothelial function is impaired in postmenopausal women. Both estrogen and raloxifene regimens may improve endothelial functions in healthy postmenopausal women. The direct protective effects of these HT on the healthy endothelium may be more remarkable than the favorable effects on lipid profile.
authors.affiliation: Ege University Faculty of Medicine, Department of Obstetrics and Gynecology, Bornova 35100, İzmir, Turkey. leventakman@gmail.com
authors.forename: Levent
authors.initials: L
authors.lastname: Akman
authors.forename: Hamza
authors.initials: H
authors.lastname: Duygu
authors.forename: Fuat
authors.initials: F
authors.lastname: Akercan
authors.forename: Murat
authors.initials: M
authors.lastname: Ulukus
authors.forename: Filiz
authors.initials: F
authors.lastname: Ozerkan
authors.forename: Mustafa
authors.initials: M
authors.lastname: Akin
mesh_terms: D000328:Adult; D001916:Brachial Artery / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000502:physiology; D004338:Drug Combinations; D004730:Endothelium, Vascular / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000502:physiology; D015914:Estrogen Replacement Therapy / Q000009:adverse effects / Q000379:methods*; D004966:Estrogens, Conjugated (USP) / Q000494:pharmacology*; D005260:Female; D006262:Health; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000494:pharmacology*; D008875:Middle Aged; D009652:Norpregnenes / Q000494:pharmacology; D017698:Postmenopause / Q000187:drug effects / Q000502:physiology; D020849:Raloxifene Hydrochloride / Q000494:pharmacology*; D014463:Ultrasonography; D014664:Vasodilation / Q000187:drug effects
chemical_list: D004338:Drug Combinations; D004966:Estrogens, Conjugated (USP); D009652:Norpregnenes; D020849:Raloxifene Hydrochloride; D017258:Medroxyprogesterone Acetate; C027385:tibolone